Clinical Trial Update: PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for PAVES evaluating Pegfilgrastim anti-VEGF strategy in colorectal cancer; status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• PAVES (Pegfilgrastim anti-vascular endothelial growth factor (VEGF) evaluation)

Snippet

Sponsor: Amgen | Conditions: Cancer, Colon Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-01-07